US Patent

US10610125 — Methods and compositions for cell-proliferation-related disorders

Method of Use · Assigned to Agios Pharmaceuticals Inc · Expires 2030-06-21 · 4y remaining

Vulnerability score 51/100 Moderate — design-around opportunities exist

What this patent protects

This patent describes methods for treating and evaluating subjects with neoactive mutants.

USPTO Abstract

Methods of treating and evaluating subjects having neoactive mutants are described herein.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2087 — enasidenib-mesylate
U-2087 — enasidenib-mesylate
U-2784 — Tibsovo

Patent Metadata

Patent number
US10610125
Jurisdiction
US
Classification
Method of Use
Expires
2030-06-21
Drug substance claim
No
Drug product claim
No
Assignee
Agios Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.